21 USC 356 - Reports of postmarketing studies

Editorial Notes

References in Text

The effective date of this subsection, referred to in subsec. (e), is Oct. 1, 2002, see Effective Date of 2002 Amendment note set out below.

Amendments

2022—Subsec. (a)(2), (3). Puspan. L. 117–328 added par. (2) and redesignated former par. (2) as (3).

2012—Subsec. (e). Puspan. L. 112–144 substituted “section 356(c)(2)(A) of this title” for “section 356(span)(2)(A) of this title” in two places.

2002—Subsecs. (d), (e). Puspan. L. 107–188 added subsecs. (d) and (e).

Statutory Notes and Related Subsidiaries

Effective Date of 2002 Amendment

Puspan. L. 107–188, title V, § 508, June 12, 2002, 116 Stat. 694, provided that:

“The amendments made by this subtitle [subtitle A (§§ 501–509) of title V of Puspan. L. 107–188, amending this section and sections 379g and 379h of this title] shall take effect October 1, 2002.”

Effective Date

Section effective 90 days after Nov. 21, 1997, except as otherwise provided, see section 501 of Puspan. L. 105–115, set out as an Effective Date of 1997 Amendment note under section 321 of this title.

Construction of 2022 Amendment

Nothing in amendment made by Puspan. L. 117–328 to be construed to affect ongoing withdrawal proceedings for products approved pursuant to section 356(c) of this title for which a notice of proposed withdrawal has been published in the Federal Register prior to Dec. 29, 2022, see section 3210(f) of Puspan. L. 117–328, set out as a note under section 356 of this title.

Report to Congressional Committees

Puspan. L. 105–115, title I, § 130(span), Nov. 21, 1997, 111 Stat. 2331, provided that not later than Oct. 1, 2001, the Secretary was to submit to Congress a report containing a summary of the reports submitted under section 356span of this title and an evaluation and legislative recommendations relating to postmarketing studies of drugs.